134 related articles for article (PubMed ID: 17627167)
1. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin D expression in renal cell cancer-clinical implications.
Merseburger AS; Hennenlotter J; Simon P; Ohneseit PA; Kuehs U; Kruck S; Koch E; Vogel U; Stenzl A; Kuczyk MA
Eur Urol; 2005 Sep; 48(3):519-26. PubMed ID: 16115525
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
4. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
[TBL] [Abstract][Full Text] [Related]
5. Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay.
Brouillet JP; Dufour F; Lemamy G; Garcia M; Schlup N; Grenier J; Mani JC; Rochefort H
Cancer; 1997 Jun; 79(11):2132-6. PubMed ID: 9179059
[TBL] [Abstract][Full Text] [Related]
6. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
8. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
Karakiewicz PI; Hutterer GC; Trinh QD; Jeldres C; Perrotte P; Gallina A; Tostain J; Patard JJ
Cancer; 2007 Sep; 110(6):1241-7. PubMed ID: 17639589
[TBL] [Abstract][Full Text] [Related]
12. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade.
Sözen S; Coskun U; Sancak B; Bukan N; Günel N; Tunc L; Bozkirli I
Neoplasma; 2004; 51(1):25-9. PubMed ID: 15004655
[TBL] [Abstract][Full Text] [Related]
14. Serum protein profiling to identify biomarkers for small renal cell carcinoma.
Xu G; Hou CR; Jiang HW; Xiang CQ; Shi N; Yuan HC; Ding Q; Zhang YF
Indian J Biochem Biophys; 2010 Aug; 47(4):211-8. PubMed ID: 21174948
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
Szajda SD; Snarska J; Jankowska A; Roszkowska-Jakimiec W; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(82-83):388-93. PubMed ID: 18613372
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer.
Manuel Del Casar J; Vizoso FJ; Abdel-Laa O; Sanz L; Martín A; Daniela Corte M; Bongera M; García Muñiz JL; Fueyo A
J Surg Oncol; 2004 Apr; 86(1):16-21. PubMed ID: 15048675
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive acidic protein detects high nuclear grade localized renal cell carcinoma.
Kawata N; Yamaguchi K; Hirakata H; Hachiya T; Yoshida T; Takimoto Y
Urology; 2005 Oct; 66(4):736-40. PubMed ID: 16230127
[TBL] [Abstract][Full Text] [Related]
18. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.
Klepzig M; Sauer-Eppel H; Jonas D; Oremek GM
Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Skrk J
Neoplasma; 2001; 48(1):66-71. PubMed ID: 11327540
[TBL] [Abstract][Full Text] [Related]
20. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma.
Horiguchi A; Ito K; Sumitomo M; Kimura F; Asano T; Hayakawa M
Jpn J Clin Oncol; 2008 Feb; 38(2):106-11. PubMed ID: 18245516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
